Winrevair (sotatercept-csrk) - BMS, Merck (MSD)
Sotatercept in Pediatric Pulmonary Hypertension: Promising Hemodynamic Findings, but Are We Extrapolating Too Far? (PubMed, Pediatr Cardiol) - Sep 19, 2026 - "However, the small and heterogeneous patient cohort-which also included patients with Group 3 pulmonary hypertension and uncorrected Eisenmenger physiology-limits the generalizability of these findings. These points should be taken into account when evaluating the potential benefits of sotatercept in a broader pediatric population with pulmonary arterial hypertension." 
Journal • Cardiovascular • Hypertension • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
http://www.ncbi.nlm.nih.gov/pubmed/42760440
 
Sep 19, 2026
 
Prev Next